REFERENCES
1. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord 2008;23:837-44.
2. Aquino CC, Fox SH. Clinical spectrum of levodopa-induced complications. Mov Disord 2015;1:80-9.
3. Manson, A., P. Stirpe and A. Schrag . Levodopa-induced-dyskinesias clinical features, incidence, risk factors, management and impact on quality of life.J Parkinsons Dis 2012;2(3):189-198.
4. Zhu, K., J. J. van Hilten, H. Putter and J. Marinus. Risk factors for hallucinations in Parkinson’s disease: results from a large prospective cohort study. Mov Disord 2013;28(6):755-762.
5. Friedman, J. H. Parkinson disease psychosis: Update. Behav Neurol 2013;27(4): 469-477.
6. Waters, S., C. Sonesson, P. Svensson, J. Tedroff, M. Carta, E. Ljung, J. Gunnergren, M. Edling, B. Svanberg, A. Fagerberg, J. Kullingsjo, S. Hjorth and N. Waters. ”Preclinical Pharmacology of [2-(3-Fluoro-5-Methanesulfonyl-phenoxy)Ethyl](Propyl)amine (IRL790), a Novel Dopamine Transmission Modulator for the Treatment of Motor and Psychiatric Complications in Parkinson Disease.” J Pharmacol Exp Ther 2020;374(1):113-125.
7. Guideline on bioanalytical method validation 21 July 2011.
8. Fitzgerald P, Dinan TG. Prolactin and dopamine: what is the connection? A review article. J Psychopharmacol. 2008;22(2 Suppl):12-9.